Hennon Mark W, DeGraaff Luke H, Groman Adrienne, Demmy Todd L, Yendamuri Sai
Department of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, NY, USA.
Department of Surgery, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, USA.
Eur J Cardiothorac Surg. 2020 May 1;57(5):888-895. doi: 10.1093/ejcts/ezz320.
Proponents of open thoracotomy (OPEN) and robot-assisted thoracic surgery (RATS) claim its oncological superiority over video-assisted thoracic surgery (VATS) in terms of the accuracy of lymph node staging.
The National Cancer Database was queried for patients with non-small-cell lung cancer (NSCLC) undergoing lobectomy without neoadjuvant therapy from 2010 to 2014. Nodal upstaging rates were compared using a surgical approach. Overall survival adjusted for confounding variables was examined using the Cox proportional hazards model.
A total of 64 676 patients fulfilled the selection criteria. The number of patients who underwent lobectomy by RATS, VATS and OPEN approaches was 5470 (8.5%), 17 545 (27.1%) and 41 661 (64.4%), respectively. The mean number of lymph nodes examined for each of these approaches was 10.9, 11.3 and 10 (P < 0.01) and upstaging rates were 11.2%, 11.7% and 12.6% (P < 0.01), respectively. For patients with clinical stage I disease (N = 46 826; RATS = 4338, VATS = 13 416 and OPEN = 29 072), the mean lymph nodes examined were 10.6, 10.8 and 9.4 (P < 0.01), and upstaging rates were 10.8%, 11.1% and 12.1% (P < 0.01), respectively. A multivariable analysis suggested an association with improved survival with RATS and VATS compared with OPEN surgery [hazard ratio (HR) = 0.89 and 0.89, respectively; P < 0.01] for patients with all stages. In stage I disease, VATS but not RATS was associated with increased overall survival compared with the OPEN approach (HR = 0.81; P < 0.01).
RATS lobectomy is not superior to VATS lobectomy with respect to lymph node yield or upstaging of NSCLC. Increased nodal upstaging by the OPEN approach does not confer a survival advantage in any stage of NSCLC and may be associated with decreased overall survival.
开胸手术(OPEN)和机器人辅助胸外科手术(RATS)的支持者称,在淋巴结分期准确性方面,它们在肿瘤学上优于电视辅助胸腔镜手术(VATS)。
查询国家癌症数据库中2010年至2014年接受肺叶切除术且未接受新辅助治疗的非小细胞肺癌(NSCLC)患者。使用手术方法比较淋巴结升级率。使用Cox比例风险模型检查调整混杂变量后的总生存率。
共有64676例患者符合入选标准。通过RATS、VATS和OPEN方法接受肺叶切除术的患者数量分别为5470例(8.5%)、17545例(27.1%)和41661例(64.4%)。这些方法中每种方法检查的平均淋巴结数量分别为10.9、11.3和10个(P<0.01),升级率分别为11.2%、11.7%和12.6%(P<0.01)。对于临床I期疾病患者(N = 46826;RATS = 4338,VATS = 13416,OPEN = 29072),检查的平均淋巴结数量分别为10.6、10.8和9.4个(P<0.01),升级率分别为10.8%、11.1%和12.1%(P<0.01)。多变量分析表明,与OPEN手术相比,RATS和VATS与所有阶段患者的生存率提高相关[风险比(HR)分别为0.89和0.89;P<0.01]。在I期疾病中,与OPEN方法相比,VATS而非RATS与总生存率增加相关(HR = 0.81;P<0.01)。
在NSCLC的淋巴结获取或升级方面,RATS肺叶切除术并不优于VATS肺叶切除术。OPEN方法导致的淋巴结升级增加在NSCLC的任何阶段都没有生存优势,并且可能与总生存率降低相关。